ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Aurinia reports favourable assessment of LUPKYNIS in ICER pharmaceutical-technology
March 18, 2021Aurinia Pharmaceuticals (IPHAF) has announced a positive cost-effectiveness assessment of LUPKYNIS (voclosporin) based on the Institute for Clinical and Economic Review (ICER) revised evidence report analysis. -
Catalent, Aurinia Ink LUPKYNIS Commercial Supply Pact contractpharma
February 20, 2021Catalent has signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals for LUPKYNIS (voclosporin), a drug to treat adult patients with lupus nephritis (LN).
Pharma Sources Insight January 2025
